Crohn's Disease - Pipeline Review, H2 2014

Date: October 30, 2014
Pages: 390
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C77E8F42085EN
Leaflet:

Download PDF Leaflet

Crohn's Disease - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Crohn's Disease - Pipeline Review, H2 2014’, provides an overview of the Crohn's Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Crohn's Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Crohn's Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Crohn's Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Crohn's Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Crohn's Disease Overview
Therapeutics Development
Pipeline Products for Crohn's Disease - Overview
Pipeline Products for Crohn's Disease - Comparative Analysis
Crohn's Disease - Therapeutics under Development by Companies
Crohn's Disease - Therapeutics under Investigation by Universities/Institutes
Crohn's Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Crohn's Disease - Products under Development by Companies
Crohn's Disease - Products under Investigation by Universities/Institutes
Crohn's Disease - Companies Involved in Therapeutics Development
4SC AG
AB Science
AbbVie Inc.
Alba Therapeutics Corporation
Alfa Wassermann S.p.A
Allozyne, Inc.
AlphaMab Co., Ltd
Amgen Inc.
Ampio Pharmaceuticals, Inc.
Amunix, Inc.
AstraZeneca PLC
Biocon Limited
BioLineRx, Ltd.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Calypso Biotech SA
Celgene Corporation
Celltrion, Inc.
ChemoCentryx, Inc.
ChironWells GmbH
CIMAB S.A.
CLL Pharma
Daiichi Sankyo Company, Limited
DBV Technologies SA
Delenex Therapeutics AG
Effimune SAS
Eisai Co., Ltd.
Eli Lilly and Company
Emergent BioSolutions Inc.
Enlivex Therapeutics Ltd
Enzo Biochem, Inc.
Epirus Biopharmaceuticals, Inc.
Farmacija d.o.o. Tuzla
Ferring International Center S.A.
Galapagos NV
Genfit SA
Genor BioPharma Co., Ltd.
Gilead Sciences, Inc.
GT Biologics Limited
iCo Therapeutics Inc.
Immune Response BioPharma, Inc.
Immunotherapix SAS
Inbiopro Solutions Pvt. Ltd.
InflammatoRx inc.
Innovent Biologics, Inc.
Innovimmune Biotherapeutics, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Kangstem Holdings Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Medestea Research & Production S.p.A.
Mesoblast Limited
Mitsubishi Tanabe Pharma Corporation
Neovacs SA
Novo Nordisk A/S
Oncobiologics, Inc.
Oncodesign SA
Pfizer Inc.
Pieris AG
Pluristem Therapeutics Inc.
Protalix BioTherapeutics, Inc.
Qu Biologics Inc.
RedHill Biopharma Ltd.
S.L.A. Pharma AG
Sandoz Inc.
Sanofi
Selexys Pharmaceuticals Corporation
Sigmoid Pharma Limited
Soligenix, Inc.
Stelic Institute & Co.
Sylentis S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
Tillotts Pharma AG
Toray Industries, Inc.
Trino Therapeutics Ltd
TxCell SA
Virobay Inc.
Winston Pharmaceuticals, Inc.
Crohn's Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(mesalamine + N-acetylcysteine) - Drug Profile
(metenkefalin + tridecactide) - Drug Profile
(rifabutin + clarithromycin + clofazimine) - Drug Profile
AB-0045 - Drug Profile
abrilumab - Drug Profile
ABS-11 - Drug Profile
adalimumab - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
Alequel - Drug Profile
AMG-139 - Drug Profile
Ampion - Drug Profile
AMX-256 - Drug Profile
Anti-S100A9 Monoclonal Antibody - Drug Profile
Antibodies to Inhibit MMP-2 and MMP-9 for Immunology and Gastrointestinal Disorders - Drug Profile
Antibodies to Target Metallothioneins for Ulcerative Colitis and Crohns Disease - Drug Profile
ApoCell - Drug Profile
apremilast - Drug Profile
Atrosab - Drug Profile
AZ-17 - Drug Profile
bertilimumab - Drug Profile
BI-655066 - Drug Profile
Biologic for Crohn's Disease - Drug Profile
BL-5040 - Drug Profile
budesonide ER - Drug Profile
CALY-001 - Drug Profile
cenplacel-L - Drug Profile
cyclosporine - Drug Profile
Dendritic Cell Therapy for Crohn’s Disease - Drug Profile
DLX-105 - Drug Profile
Drug for Crohn's Disease - Drug Profile
Drugs to Inhibit TNFR25 for Gastrointestinal Disorders - Drug Profile
E-6011 - Drug Profile
eldelumab - Drug Profile
ES-210 - Drug Profile
etanercept biosimilar - Drug Profile
ETX-201 - Drug Profile
FE-999301 - Drug Profile
FFP-102 - Drug Profile
filgotinib - Drug Profile
Furestem-CD - Drug Profile
GED-0301 - Drug Profile
GFT-505 - Drug Profile
IAC VITA - Drug Profile
IBI-303 - Drug Profile
IBPM-004AM - Drug Profile
IBPM-005IX - Drug Profile
infliximab - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
INV-88 - Drug Profile
IR-777 - Drug Profile
ITP-01 - Drug Profile
JKB-122 - Drug Profile
JNJ-40346527 - Drug Profile
KRP-203 - Drug Profile
larazotide acetate - Drug Profile
LBP-001 - Drug Profile
Leukothera - Drug Profile
masitinib - Drug Profile
mercaptopurine DR - Drug Profile
mesalamine CR - Drug Profile
metronidazole - Drug Profile
MLN-3126 - Drug Profile
Monoclonal Antibody to Inhibit TNF Alpha for Crohns Disease and Rheumatoid Arthritis - Drug Profile
MP-196 - Drug Profile
MT-1303 - Drug Profile
naltrexone - Drug Profile
naltrexone - Drug Profile
NAT-100 - Drug Profile
NN-8555 - Drug Profile
NN-8828 - Drug Profile
ONS-3015 - Drug Profile
Ova-Treg - Drug Profile
Peptides to Inhibit IL-1 Beta for Ulcerative Colitis and Crohn's Disease - Drug Profile
PF-00547659 - Drug Profile
PF-04236921 - Drug Profile
PF-06480605 - Drug Profile
PH-44 - Drug Profile
PH-46A - Drug Profile
PH-5 - Drug Profile
PRS-190 - Drug Profile
QBECO - Drug Profile
remestemcel-L - Drug Profile
rifaximin - Drug Profile
rifaximin DR - Drug Profile
RNAi Oligonucleotide for Arthritis and Gastrointestinal Disorders - Drug Profile
SAR-252067 - Drug Profile
SelK-2 - Drug Profile
SGX-203 - Drug Profile
Small Molecule to Agonize OP3 Receptor for Inflammatory Bowel Diseases - Drug Profile
Small Molecules for Gastrointestinal Disorders - Drug Profile
Small Molecules to Inhibit RIP2 for Crohn's Disease and Polyarthritis - Drug Profile
SQ-641 - Drug Profile
Stem Cell Therapy for Crohn’s Disease - Drug Profile
Stem Cell Therapy for Inflammatory Bowel Disease - Drug Profile
STNM-01 - Drug Profile
SYN-1002 - Drug Profile
TNF-Kinoid - Drug Profile
tofacitinib - Drug Profile
TRK-170 - Drug Profile
ustekinumab - Drug Profile
VBY-036 - Drug Profile
vedolizumab - Drug Profile
vercirnon sodium - Drug Profile
VGX-1027 - Drug Profile
vidofludimus - Drug Profile
zucapsaicin - Drug Profile
Crohn's Disease - Recent Pipeline Updates
Crohn's Disease - Dormant Projects
Crohn's Disease - Discontinued Products
Crohn's Disease - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Crohn's Disease, H2 2014
Number of Products under Development for Crohn's Disease - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Development by Companies, H2 2014 (Contd..1)
Number of Products under Development by Companies, H2 2014 (Contd..2)
Number of Products under Development by Companies, H2 2014 (Contd..3)
Number of Products under Development by Companies, H2 2014 (Contd..4)
Number of Products under Development by Companies, H2 2014 (Contd..5)
Number of Products under Development by Companies, H2 2014 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Comparative Analysis by Unknown Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Development by Companies, H2 2014 (Contd..1)
Products under Development by Companies, H2 2014 (Contd..2)
Products under Development by Companies, H2 2014 (Contd..3)
Products under Development by Companies, H2 2014 (Contd..4)
Products under Development by Companies, H2 2014 (Contd..5)
Products under Development by Companies, H2 2014 (Contd..6)
Products under Development by Companies, H2 2014 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2014
Crohn's Disease - Pipeline by 4SC AG, H2 2014
Crohn's Disease - Pipeline by AB Science, H2 2014
Crohn's Disease - Pipeline by AbbVie Inc., H2 2014
Crohn's Disease - Pipeline by Alba Therapeutics Corporation, H2 2014
Crohn's Disease - Pipeline by Alfa Wassermann S.p.A, H2 2014
Crohn's Disease - Pipeline by Allozyne, Inc., H2 2014
Crohn's Disease - Pipeline by AlphaMab Co., Ltd, H2 2014
Crohn's Disease - Pipeline by Altheus Therapeutics, Inc., H2 2014
Crohn's Disease - Pipeline by Amgen Inc., H2 2014
Crohn's Disease - Pipeline by Ampio Pharmaceuticals, Inc., H2 2014
Crohn's Disease - Pipeline by Amunix, Inc., H2 2014
Crohn's Disease - Pipeline by AstraZeneca PLC, H2 2014
Crohn's Disease - Pipeline by Biocon Limited, H2 2014
Crohn's Disease - Pipeline by BioLineRx, Ltd., H2 2014
Crohn's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2014
Crohn's Disease - Pipeline by Bristol-Myers Squibb Company, H2 2014
Crohn's Disease - Pipeline by Calypso Biotech SA, H2 2014
Crohn's Disease - Pipeline by Celgene Corporation, H2 2014
Crohn's Disease - Pipeline by Celltrion, Inc., H2 2014
Crohn's Disease - Pipeline by ChemoCentryx, Inc., H2 2014
Crohn's Disease - Pipeline by ChironWells GmbH, H2 2014
Crohn's Disease - Pipeline by CIMAB S.A., H2 2014
Crohn's Disease - Pipeline by CLL Pharma, H2 2014
Crohn's Disease - Pipeline by Daiichi Sankyo Company, Limited, H2 2014
Crohn's Disease - Pipeline by DBV Technologies SA, H2 2014
Crohn's Disease - Pipeline by Delenex Therapeutics AG, H2 2014
Crohn's Disease - Pipeline by Effimune SAS, H2 2014
Crohn's Disease - Pipeline by Eisai Co., Ltd., H2 2014
Crohn's Disease - Pipeline by Eli Lilly and Company, H2 2014
Crohn's Disease - Pipeline by Emergent BioSolutions Inc., H2 2014
Crohn's Disease - Pipeline by Enlivex Therapeutics Ltd, H2 2014
Crohn's Disease - Pipeline by Enzo Biochem, Inc., H2 2014
Crohn's Disease - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014
Crohn's Disease - Pipeline by Farmacija d.o.o. Tuzla, H2 2014
Crohn's Disease - Pipeline by Ferring International Center S.A., H2 2014
Crohn's Disease - Pipeline by Galapagos NV, H2 2014
Crohn's Disease - Pipeline by Genfit SA, H2 2014
Crohn's Disease - Pipeline by Genor BioPharma Co., Ltd., H2 2014
Crohn's Disease - Pipeline by Gilead Sciences, Inc., H2 2014
Crohn's Disease - Pipeline by GT Biologics Limited, H2 2014
Crohn's Disease - Pipeline by iCo Therapeutics Inc., H2 2014
Crohn's Disease - Pipeline by Immune Response BioPharma, Inc., H2 2014
Crohn's Disease - Pipeline by Immunotherapix SAS, H2 2014
Crohn's Disease - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014
Crohn's Disease - Pipeline by InflammatoRx inc., H2 2014
Crohn's Disease - Pipeline by Innovent Biologics, Inc., H2 2014
Crohn's Disease - Pipeline by Innovimmune Biotherapeutics, Inc., H2 2014
Crohn's Disease - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014
Crohn's Disease - Pipeline by Johnson & Johnson, H2 2014
Crohn's Disease - Pipeline by Kangstem Holdings Co., Ltd., H2 2014
Crohn's Disease - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014
Crohn's Disease - Pipeline by Medestea Research & Production S.p.A., H2 2014
Crohn's Disease - Pipeline by Mesoblast Limited, H2 2014
Crohn's Disease - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014
Crohn's Disease - Pipeline by Neovacs SA, H2 2014
Crohn's Disease - Pipeline by Novo Nordisk A/S, H2 2014
Crohn's Disease - Pipeline by Oncobiologics, Inc., H2 2014
Crohn's Disease - Pipeline by Oncodesign SA, H2 2014
Crohn's Disease - Pipeline by Pfizer Inc., H2 2014
Crohn's Disease - Pipeline by Pieris AG, H2 2014
Crohn's Disease - Pipeline by Pluristem Therapeutics Inc., H2 2014
Crohn's Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2014
Crohn's Disease - Pipeline by Qu Biologics Inc., H2 2014
Crohn's Disease - Pipeline by RedHill Biopharma Ltd., H2 2014
Crohn's Disease - Pipeline by S.L.A. Pharma AG, H2 2014
Crohn's Disease - Pipeline by Sandoz Inc., H2 2014
Crohn's Disease - Pipeline by Sanofi, H2 2014
Crohn's Disease - Pipeline by Selexys Pharmaceuticals Corporation, H2 2014
Crohn's Disease - Pipeline by Sigmoid Pharma Limited, H2 2014
Crohn's Disease - Pipeline by Soligenix, Inc., H2 2014
Crohn's Disease - Pipeline by Stelic Institute & Co., H2 2014
Crohn's Disease - Pipeline by Sylentis S.A., H2 2014
Crohn's Disease - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014
Crohn's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014
Crohn's Disease - Pipeline by Tillotts Pharma AG, H2 2014
Crohn's Disease - Pipeline by Toray Industries, Inc., H2 2014
Crohn's Disease - Pipeline by Trino Therapeutics Ltd, H2 2014
Crohn's Disease - Pipeline by TxCell SA, H2 2014
Crohn's Disease - Pipeline by Virobay Inc., H2 2014
Crohn's Disease - Pipeline by Winston Pharmaceuticals, Inc., H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Crohn's Disease Therapeutics - Recent Pipeline Updates, H2 2014
Crohn's Disease - Dormant Projects, H2 2014
Crohn's Disease - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Crohn's Disease, H2 2014
Number of Products under Development for Crohn's Disease - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

COMPANIES MENTIONED

4SC AG
AB Science
AbbVie Inc.
Alba Therapeutics Corporation
Alfa Wassermann S.p.A
Allozyne, Inc.
AlphaMab Co., Ltd
Amgen Inc.
Ampio Pharmaceuticals, Inc.
Amunix, Inc.
AstraZeneca PLC
Biocon Limited
BioLineRx, Ltd.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Calypso Biotech SA
Celgene Corporation
Celltrion, Inc.
ChemoCentryx, Inc.
ChironWells GmbH
CIMAB S.A.
CLL Pharma
Daiichi Sankyo Company, Limited
DBV Technologies SA
Delenex Therapeutics AG
Effimune SAS
Eisai Co., Ltd.
Eli Lilly and Company
Emergent BioSolutions Inc.
Enlivex Therapeutics Ltd
Enzo Biochem, Inc.
Epirus Biopharmaceuticals, Inc.
Farmacija d.o.o. Tuzla
Ferring International Center S.A.
Galapagos NV
Genfit SA
Genor BioPharma Co., Ltd.
Gilead Sciences, Inc.
GT Biologics Limited
iCo Therapeutics Inc.
Immune Response BioPharma, Inc.
Immunotherapix SAS
Inbiopro Solutions Pvt. Ltd.
InflammatoRx inc.
Innovent Biologics, Inc.
Innovimmune Biotherapeutics, Inc.
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Kangstem Holdings Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Medestea Research & Production S.p.A.
Mesoblast Limited
Mitsubishi Tanabe Pharma Corporation
Neovacs SA
Novo Nordisk A/S
Oncobiologics, Inc.
Oncodesign SA
Pfizer Inc.
Pieris AG
Pluristem Therapeutics Inc.
Protalix BioTherapeutics, Inc.
Qu Biologics Inc.
RedHill Biopharma Ltd.
S.L.A. Pharma AG
Sandoz Inc.
Sanofi
Selexys Pharmaceuticals Corporation
Sigmoid Pharma Limited
Soligenix, Inc.
Stelic Institute & Co.
Sylentis S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
Tillotts Pharma AG
Toray Industries, Inc.
Trino Therapeutics Ltd
TxCell SA
Virobay Inc.
Winston Pharmaceuticals, Inc.
Skip to top


Celiac Disease - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 82 pages

Ask Your Question

Crohn's Disease - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: